ES2665543B1 - Péptidos de unión a FOXP3 y usos de los mismos - Google Patents

Péptidos de unión a FOXP3 y usos de los mismos Download PDF

Info

Publication number
ES2665543B1
ES2665543B1 ES201700439A ES201700439A ES2665543B1 ES 2665543 B1 ES2665543 B1 ES 2665543B1 ES 201700439 A ES201700439 A ES 201700439A ES 201700439 A ES201700439 A ES 201700439A ES 2665543 B1 ES2665543 B1 ES 2665543B1
Authority
ES
Spain
Prior art keywords
amino acid
alkyl
cio
peptide
conservative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201700439A
Other languages
English (en)
Spanish (es)
Other versions
ES2665543A1 (es
Inventor
Lagar Inés Noelia Casares
Sagastibelza Juan José Lasarte
Moreda Teresa Lozano
Santamarina Julen Oyarzabal
Gracia María Obdulia Rabal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion para la Investigacion Medica Aplicada
Original Assignee
Fundacion para la Investigacion Medica Aplicada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion para la Investigacion Medica Aplicada filed Critical Fundacion para la Investigacion Medica Aplicada
Publication of ES2665543A1 publication Critical patent/ES2665543A1/es
Application granted granted Critical
Publication of ES2665543B1 publication Critical patent/ES2665543B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES201700439A 2016-10-26 2017-03-29 Péptidos de unión a FOXP3 y usos de los mismos Active ES2665543B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16195686.7 2016-10-26
EP16195686 2016-10-26

Publications (2)

Publication Number Publication Date
ES2665543A1 ES2665543A1 (es) 2018-04-26
ES2665543B1 true ES2665543B1 (es) 2019-02-12

Family

ID=57209245

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201700439A Active ES2665543B1 (es) 2016-10-26 2017-03-29 Péptidos de unión a FOXP3 y usos de los mismos

Country Status (6)

Country Link
US (2) US10654896B2 (https=)
EP (1) EP3532482A1 (https=)
JP (2) JP7212942B2 (https=)
AU (1) AU2017349979B2 (https=)
ES (1) ES2665543B1 (https=)
WO (1) WO2018077716A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2665543B1 (es) * 2016-10-26 2019-02-12 Fundacion Para La Investig Medica Aplicada Péptidos de unión a FOXP3 y usos de los mismos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP1105479B1 (en) 1998-08-11 2011-01-12 Darwin Discovery Limited Identification of the gene causing the mouse scurfy phenotype and its human ortholog
WO2009020865A1 (en) 2007-08-03 2009-02-12 The Board Of Regents Of The University Of Nebraska Surface-modified nanoparticles for intracellular delivery of therapeutic agents and composition for making same
ES2328776B1 (es) * 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
CA2939711C (en) * 2014-02-21 2020-09-29 Cellectis Method for in situ inhibition of regulatory t cells
ES2665543B1 (es) * 2016-10-26 2019-02-12 Fundacion Para La Investig Medica Aplicada Péptidos de unión a FOXP3 y usos de los mismos

Also Published As

Publication number Publication date
US20200317733A1 (en) 2020-10-08
AU2017349979B2 (en) 2021-10-14
US10654896B2 (en) 2020-05-19
JP2022191303A (ja) 2022-12-27
EP3532482A1 (en) 2019-09-04
JP2020500167A (ja) 2020-01-09
JP7212942B2 (ja) 2023-01-26
AU2017349979A1 (en) 2019-05-16
ES2665543A1 (es) 2018-04-26
WO2018077716A1 (en) 2018-05-03
US20190276496A1 (en) 2019-09-12
US11560407B2 (en) 2023-01-24

Similar Documents

Publication Publication Date Title
JP7248247B2 (ja) Wt1抗原ペプチドコンジュゲートワクチン
US12453762B2 (en) Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of glioblastoma
JP7346291B2 (ja) 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びtlrペプチドアゴニストを含む融合体
JP6671956B2 (ja) Erap1によるトリミング機能をきっかけとしたコンジュゲートワクチン
ES2665543B1 (es) Péptidos de unión a FOXP3 y usos de los mismos
KR102401796B1 (ko) 신규의 펩타이드 기재 pcsk9 백신
JP7302887B2 (ja) 抗がんペプチド及びその使用
HK1220471B (zh) Wt1抗原肽缀合物疫苗
EA049338B1 (ru) Новый комплекс, содержащий проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2665543

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20190212